Artwork

Content provided by Levine Media Group. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Levine Media Group or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

A Biologic Designed to Treat Acute Exacerbations of Asthma and COPD

26:23
 
Share
 

Manage episode 489410506 series 49047
Content provided by Levine Media Group. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Levine Media Group or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.

Though there are plenty of therapeutic alternatives for asthma and chronic obstructive pulmonary disease, or COPD, there are no approved biologics for treating acute exacerbations of these conditions. Connect Biopharma believes that’s an opportunity. It's experimental therapy rademikibart has shown promise treating exacerbations and providing sustained improvements. We spoke to Barry Quart, CEO of Connect Biopharma, about the unmet need the company is seeking to address, how rademikibart works, and Connect’s repositioning as a U.S.-centric company.

  continue reading

568 episodes

Artwork
iconShare
 
Manage episode 489410506 series 49047
Content provided by Levine Media Group. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Levine Media Group or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.

Though there are plenty of therapeutic alternatives for asthma and chronic obstructive pulmonary disease, or COPD, there are no approved biologics for treating acute exacerbations of these conditions. Connect Biopharma believes that’s an opportunity. It's experimental therapy rademikibart has shown promise treating exacerbations and providing sustained improvements. We spoke to Barry Quart, CEO of Connect Biopharma, about the unmet need the company is seeking to address, how rademikibart works, and Connect’s repositioning as a U.S.-centric company.

  continue reading

568 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide

Copyright 2025 | Privacy Policy | Terms of Service | | Copyright
Listen to this show while you explore
Play